US 12,083,152 B2
Agent for improving mitochondrial function
Takashi Ito, Hamamatsu (JP); Mitsutoshi Setou, Hamamatsu (JP); Satoru Ozaki, Tokyo (JP); Chinami Mizoguchi, Tokyo (JP); and Yukio Asami, Tokyo (JP)
Assigned to MEIJI CO., LTD., Tokyo (JP); and NATIONAL UNIVERSITY CORPORATION HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE, Shizuoka (JP)
Appl. No. 17/279,941
Filed by MEIJI CO., LTD., Tokyo (JP); and NATIONAL UNIVERSITY CORPORATION HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE, Shizuoka (JP)
PCT Filed Sep. 26, 2019, PCT No. PCT/JP2019/038014
§ 371(c)(1), (2) Date Sep. 20, 2021,
PCT Pub. No. WO2020/067368, PCT Pub. Date Apr. 2, 2020.
Claims priority of application No. 2018-180969 (JP), filed on Sep. 26, 2018.
Prior Publication US 2022/0008489 A1, Jan. 13, 2022
Int. Cl. A61K 35/747 (2015.01); A23L 33/135 (2016.01)
CPC A61K 35/747 (2013.01) [A23L 33/135 (2016.08)] 1 Claim
 
1. A method for improving mitochondrial function, comprising: administering a therapeutically effective amount of a lactic acid bacterium belonging to Lactobacillus farciminis or Pediococcus acidilactici, or a culture of the lactic acid bacterium, to a subject in need thereof, wherein the Lactobacillus farciminis is Lactobacillus farciminis OLL204082 strain, accession number: NITE BP-02635, or the Pediococcus acidilactici is Pediococcus acidilactici OB7260 strain, accession number: NITE BP-02634.